BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.62390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lourenço MS, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. World J Hepatol 2022; 14(1): 195-208 [DOI: 10.4254/wjh.v14.i1.195] [Reference Citation Analysis]
3 Mousa MHA, Ahmed NS, Schwedtmann K, Frakolaki E, Vassilaki N, Zoidis G, Weigand JJ, Abadi AH. Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors. Pharmaceuticals (Basel) 2021;14:292. [PMID: 33806139 DOI: 10.3390/ph14040292] [Reference Citation Analysis]
4 Ran X, Xie H, Li W. Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-Analysis. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.98798] [Reference Citation Analysis]
5 Gane E, Nahass R, Luketic V, Asante-Appiah E, Hwang P, Robertson M, Wahl J, Barr E, Haber B. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. J Viral Hepat 2017;24:895-9. [PMID: 28470815 DOI: 10.1111/jvh.12719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
6 Sood A, Duseja A, Kabrawala M, Amrose P, Goswami B, Chowdhury A, Sarin SK, Koshy A, Hyland RH, Lu S, Camus G, Stamm LM, Brainard DM, Subramanian GM, Prasad M, Bhatia S, Shah SR, Kapoor D, Shalimar, Saraswat V. Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatol Int. 2019;13:173-179. [PMID: 30790229 DOI: 10.1007/s12072-019-09927-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Knobler H, Malnick S. Hepatitis C and insulin action: An intimate relationship. World J Hepatol 2016; 8(2): 131-138 [PMID: 26807209 DOI: 10.4254/wjh.v8.i2.131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
8 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bhushan A, Ghosh S, Bhattacharjee S, Chinnaswamy S. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection. J Interferon Cytokine Res 2017;37:369-82. [PMID: 28727946 DOI: 10.1089/jir.2017.0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
10 Lougiakis N, Frakolaki E, Karmou P, Pouli N, Marakos P, Madan V, Bartenschlager R, Vassilaki N. Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism. Chem Biol Drug Des 2017;90:352-67. [PMID: 28245093 DOI: 10.1111/cbdd.12966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Han Q, Fan X, Wang X, Wang Y, Deng H, Zhang X, Zhang K, Li N, Liu Z. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virol J 2019;16:74. [PMID: 31159813 DOI: 10.1186/s12985-019-1184-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
12 Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep 2017;19:22. [PMID: 28421422 DOI: 10.1007/s11908-017-0578-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
13 Butsashvili M, Gvinjilia L, Kamkamidze G, Metreveli D, Dvali S, Rukhadze T, Gamkrelidze A, Nasrullah M, Shadaker S, Morgan J, Averhoff F. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia. BMC Res Notes 2020;13:332. [PMID: 32653020 DOI: 10.1186/s13104-020-05173-4] [Reference Citation Analysis]
14 Madhvi A, Hingane S, Srivastav R, Joshi N, Subramani C, Muthumohan R, Khasa R, Varshney S, Kalia M, Vrati S, Surjit M, Ranjith-Kumar CT. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound. Sci Rep 2017;7:5816. [PMID: 28725041 DOI: 10.1038/s41598-017-04449-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
15 Oliver M, Ortiz CC, Ortiz J. Challenging hepatitis C-infected liver transplant patients. Hepat Med 2016;8:1-8. [PMID: 26889091 DOI: 10.2147/HMER.S96110] [Reference Citation Analysis]
16 Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, Liu CH, Paik SW. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017;32:966-74. [PMID: 28005275 DOI: 10.1111/jgh.13709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
17 Gordon SC, Trudeau S, Li J, Zhou Y, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Lu M; CHeCS investigators. Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. J Clin Gastroenterol 2019;53:40-50. [PMID: 28737649 DOI: 10.1097/MCG.0000000000000872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]